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ABSTRACT
The development of high-throughput sequencing and targeted therapies has led to the emergence
of personalized medicine: a patient’s molecular profile or the presence of a specific biomarker of
drug response will correspond to a treatment recommendation made either by a physician or by
a treatment assignment algorithm. The growing number of such algorithms raises the question of
how to quantify their clinical impact knowing that a personalized medicine strategy will inherently
include different versions of treatment.
We thus specify an appropriate causal framework with multiple versions of treatment to define the
causal effects of interest for precision medicine strategies and estimate them emulating clinical trials
with observational data. Therefore, we determine whether the treatment assignment algorithm is
more efficient than different control arms: gold standard treatment, observed treatments or random
assignment of targeted treatments.
Causal estimates of the precision medicine effects are first evaluated on simulated data and they
demonstrate a lower biases and variances compared with naive estimation of the difference in ex-
pected outcome between treatment arms. The various simulations scenarios also point out the dif-
ferent bias sources depending on the clinical situation (heterogeneity of response, assignment of
observed treatments etc.). A RShiny interactive application is also provided to further explore other
user-defined scenarios. The method is then applied to data from patient-derived xenografts (PDX):
each patient tumour is implanted in several immunodeficient cloned mice later treated with differ-
ent drugs, thus providing access to all corresponding drug sensitivities for all patients. Access to
these unique pre-clinical data emulating counterfactual outcomes allows to validate the reliability of
causal estimates obtained with the proposed method.
Keywords Causal inference · Patient-derived xenografts · Precision medicine
1 Introduction
Precision medicine (PM) consists in associating the most appropriate treatment to each patient according to his or her
characteristics. This is, for instance, quite common in the clinical management of cancer patients where the choice
of treatment is increasingly influenced by the genomic alterations of the patient [1]. At the individual level, targeted
treatments has provided relevant solutions for patients with specific mutations [2]. Putting together these various
treatments, some precision medicine strategies can be defined: based on the omics profile of the patient, the treatment
most likely to be successful is chosen. If the information available is reliable, precision medicine can thus be reduced
to a treatment choice algorithm that takes as input the molecular characteristics of the patient’s tumour and outputs a
recommendation of treatment.
The question then arises of how to quantify the clinical benefit provided by these treatment algorithms. Some clinical
trials have been proposed, demonstrating both the feasibility of collecting information about mutations [3] or RNA [4]
in real-time and the clinical benefit that can be expected from these approaches for some patients [5]. However, the
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Causal inference with multiple versions of treatment and application to personalized medicine
increasing abundance of omics data and biological knowledge make it progressively easier to establish new algorithms
for precision medicine, either directly based on physician knowledge or provided by computational models [6]. For
practical reasons it is not possible to propose a real clinical trial for each new precision medicine algorithm or for any
variants, comparing standard of care with new algorithm-based treatments.
Therefore, this work provides a method to assess the clinical impact of proposed PM treatment algorithm based on
already generated data, emulating clinical trials and analyzing them in the causal inference framework [7]. First we
will define the causal estimates of the precision medicine effects (later referred to as causal estimates) we want to
assess, and the corresponding ideal clinical trials one would like to perform. Next, we will define the notations and
the causal framework we use to infer the causal effects from observational data with multiple versions of treatment,
based on the previous work by [8]. It will be briefly introduced in its main principles and then extended in order to
adapt to the characteristics of PM, in particular the multiplicity of treatment versions, i.e. targeted drugs. Then we will
apply the proposed methods to simulated data in order to investigate the different biases of the candidate methods. An
example scenario will be presented and a RShiny interactive application has been developed to further explore other
user-defined settings. Finally, the analysis of data from patient-derived xenografts (PDX) makes it possible both to
apply the methods to pre-clinical situation and to have data approximating the counterfactual responses, thus enabling
further validation of the proposed estimation methods.
2 Target trials for precision medicine: definition of causal estimates
We first specify the precision medicine effects that are to be estimated. These effects will finally be estimated based on
observational data through the causal framework and target trial emulation [7]. Thus, if we think in terms of clinical
trials, we are not trying to prove or quantify the superiority of one treatment over another but rather to evaluate the
clinical utility of a precision medicine strategy assigning treatments based on genomic features of patients. This is
therefore closer to the well-studied biomarker-based designs for clinical trials [9]. In a way, it is a matter of extending
these unidimensional biomarker-based designs to multidimensional strategies that allow a choice between quite a
number of different treatments. The potentially large number of treatments thus prompts us to draw more inspiration
from scalable biomarker-strategy designs than biomarker-stratified designs [9]. We can draw a methodological parallel
with some trials like the Tumor Chemosensitivity Assay Ovarian Cancer study in which a biochemical assay guides
the choice of preferred chemotherapy for patients in a panel of twelve different treatments [10]. More recently, some
clinical trials have been proposed that include precision medicine strategies, particularly in oncology [3, 11].
On the basis of these clinical examples, we propose three different target trials and their corresponding causal esti-
mates, the clinical relevance of which may vary according to medical contexts. Each target trial contains a precision-
medicine directed arm in which patients are treated in accordance with the precision medicine algorithm recommenda-
tions but they are differentiated from each other by alternative control arms (Figure 1). Causal effects will be estimated
solely on patients eligible for the assignment of a personalized treatment, i.e. those for whom the treatment algorithm
is able to recommend a drug.
2.1 First causal effect (CE1): comparison with a single standard
The first possible target trial is to compare the precision medicine arm with a control arm in which all patients have
been treated with the same single treatment. This could classically be the current standard of care applied to all patients
(e.g chemotherapy cancer treatment).
2.2 Second causal effect (CE2): comparison with physician’s assignment of drugs
Then, in order to propose a more comprehensive clinical assessment, we propose a second causal effect, comparing
the PM arm with the current clinical practice, i.e the assignment of the same targeted treatments by physicians in the
absence of the algorithm. This implicitly means comparing two PM strategies: the one derived from the algorithm
and the one that corresponds to current physician’s knowledge. Unlike the former, the latter may not be perfectly
deterministic depending on the heterogeneity of medical knowledge or practices. This way of defining CE2 by focusing
on the doctor’s assignment of the same treatments stems from our question of interest: to quantify the relevance of the
algorithm itself. Another vision would have been to compare the precision medicine arm with the doctor’s treatments,
allowing him to use treatments other than those of the PM arm, such as the gold-standard one described in CE1. But
the differences between the arms could then be biased by the use of treatments with different overall efficacy, changing
the focus of the question. We will therefore stick to the first definition, which is more focused on the relevance of the
algorithm.
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Figure 1: Target trials to estimate causal effect of precision medicine (PM) algorithm versus different controls.
Patients are first screened according to their eligibility for the algorithm: based on their genomic characteristics pa-
tients are recommended a specific treatment (eligible) or not (no eligible). Then eligible patients are randomized and
assigned either to PM-directed arm or to one of the alternative control arms (CE1, CE2 or CE3)
2.3 Third causal effect (CE3): comparison with random assignment of drugs
Finally, we define the CE3 effect comparing the PM arm with a control arm using exactly the same pool of treatments
assigned randomly. In this case, we measure the ability of the PM algorithm to assign treatments effectively based on
genomic features of patients. This comparison has already been considered in the context of biomarker-based clinical
trials [12]. Although this comparison with random assignment is methodologically relevant, it may not make sense
from a clinical point of view if the common clinical practice already contains strong indications (or contraindications)
for some patient-treatment associations.
3 Precision medicine causal inference with multiple versions of treatment
3.1 Causal inference and the potential outcomes framework
Now that we have defined what we want to estimate, we need to specify the method of estimation. In cases where
it would be too difficult or too early to conduct a true clinical trial we propose methods using observational data to
emulate them. Indeed, it is possible to derive estimates with a causal interpretation from observational data in the
context of the potential outcomes framework [13]. We will first describe briefly the fundamentals of this framework
before extending this framework to our precision medicine settings in section 3.2.
3.1.1 First notations and causal graph
We will use j = 1, ..., N to index the individuals in the population. Aj and Yj correspond respectively to the actual
treatment received by individual j and the outcome. In the most simple case, treatment takes values in A = {0, 1},
1 denoting the treated patients and 0 the control ones. Yj corresponds to the patient’s response to treatment. In the
case of cancer it may be a continuous value (e.g size of tumour), a binary value (e.g status or event indicator), or even
a time-to-event (e.g time to relapse or death). Only the first two cases will be discussed later. Finally, it is necessary
to take into account the possible presence of confounders influencing both A and Y and denoted Cj for individual j.
These simple relations can be summarized in a causal graph (Figure 2).
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Figure 2: Causal diagram illustrating relations between variables. Treatment A, outcome Y, and confounding
variable C.
3.1.2 Potential outcomes framework
One standard framework to estimate causal effects relies on potential outcomes [13]. This framework is sometimes
described as counterfactual because it defines variables like Yj(a) to denote the potential outcome of individual j in
case he has been treated by A = a which may be different from what we observe if Aj 6= a. These counterfactual
variables make it possible to write the causal estimands. For instance, in this context, we can easily compute the
difference in outcome between treated patients and control patients: E[Y |A = 1]− E[Y |A = 0].
However, this difference has no causal interpretation as it does not offer any guarantees as to the confounding factor,
as an unbalanced distribution of C can induce biases Thus we define another estimate: E[Y (1)]− E[Y (0)].
In this case, we compare between two ideal cohort, one in which all patients have been treated (possibly contrary
to the fact) and one in which all patients have been left in the control arm (once again, possibly contrary to the
fact). Under certain assumptions of consistency, positivity and conditional exchangeability, the potential outcomes
framework allows to estimate these counterfactual variables and therefore infer causal estimates from observational
(non-randomized) data [13, 14].
Consistency means that values of treatment under comparison represent well-defined interventions which themselves
correspond to the treatments in the data: if Aj = a, then Yj(a) = Yj .
Exchangeability means that treated and control patients are exchangeable, i.e if the treated patients had not been treated
they would have had the same outcomes as the controls, and conversely. Since we usually observe some confounders
we define conditional exchangeability to hold if cohorts are exchangeable for same values of confoundingC. Therefore
conditional exchangeability will hold if there are no unmeasured confounding: Y (a) ⊥⊥ A|C.
Positivity assumption states that the probability of being administered a certain version of treatment conditional on C
is greater than zero: if P [C = c] 6= 0, P [A = a|C = c] > 0. Intuitively, this positivity condition is required to ensure
that the defined counterfactual variables make sense and do not represent something that cannot exist.
3.1.3 Identification of causal effects
Different methods provide estimators to evaluate causal effect from observational data. Throughout the article, we will
describe essentially one method called standardization or parametric g-formula. Details on other types of estimators
are available in Supplementary Materials, sections B and C. In this simple case (Figure 2), the causal effect of treatment
A can be written with standardized means (formal proof in Supplementary Materials, section A):
E[Y (A = 1)]− E[Y (A = 0)] =
∑
c
(
E[Y |A = 1, C = c]− E[Y |A = 0, C = c]
)
× P [C = c]. (1)
Computationally, non-parametric estimation of E[Y |A = a,C = c] is usually out of reach. Thus, on real-world
dataset, E[Y |A = a,C = c] is estimated through modelling and explicit computation P [C = c] is replaced by its
empirical estimate.
3.2 Precision medicine and the multiple versions of treatment
3.2.1 A treatment with multiple versions
The statement of the theoretical framework implicitly implies the uniqueness of the versions of the treatment [15] or
at least the treatment variation irrelevance [16]. In the precision medicine case, the multiplicity of versions is inherent:
a given treatment status may encompass several drugs since a patient may be associated with several molecular agents
based on his or her genomic characteristics. A can be seen as a compound treatment [17] or a treatment with multiple
versions [8].
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Therefore, we define a variable Kj denoting the version of treatment administered to individual j. If Aj = a is the
arm to which the patient is assigned, Kaj is the molecule received, the version of treatment A = a (e.g a specific
anti-cancer drug) and Kaj ∈ Ka, the set of versions of treatment A = a. In our precision medicine problem, A = 0
will denote control patients and A = 1 the patients treated with an anti-cancer drug of the precision medicine pool.
K1 = {k11, ..., k1P } is the set of P possible targeted treatments for A = 1 patients. For the sake of simplicity we will
assume that there is only one treatment version for A = 0 controls, K0 = {k0}.
We also need to define other counterfactual variables like Kaj (a), the counterfactual version of treatment A = a if
the subject had been given the treatment level a. Thus, we finally write the counterfactual outcome as Yj(a, ka) for
individual j when treatment A has been set to a, using ka as the version of treatment a, with ka ∈ Ka. Causal relations
between variables C, A, K and Y are depicted in the causal diagram in Figure 3. It should be noted that A has no
direct influence on Y , its only effect is entirely mediated by K, which is the real treatment in the pharmacological
sense.
Figure 3: Causal diagram illustrating relations between variables under multiple versions of treatment. Treat-
ment A, version of treatment K, outcome Y, and confounding variables C and W.
In this context, we can also define the assignment of a version of treatment for patients eligible to precision medicine
algorithm. It is important to note that not all patients are necessarily eligible for the precision medicine strategy.
Indeed, the treatment assignment algorithm relies on targetable alterations to establish its recommendations. In the
absence of these, no recommendation can be offered to the patient. We denote CPM the set of eligible patient profiles
and consequently define the drug assignment algorithm as the function r which associates to each C a precision
medicine treatment version K such as:
∀j ∈ J1, NK, if Cj ∈ CPM , r(Cj) ∈ K1
3.2.2 Causal inference with multiple versions
Consequently, the multiplicity of versions prevents direct application of the framework as described in section 3.1.
The theoretical framework has however been extended to causal inference under multiple versions of treatment and
some identifiability conditions and properties have been studied, especially in the seminal article by [8]. One of the
first required adaptation to identify some causal effects is to partition confounders C and W (Figure 3). W indicates
a collection of covariates that may be causes of treatment A or version of treatment K but are not direct causes of
Y . These covariates are of special interest for causal effects identification under multiple versions of treatment. C
indicates all other covariates. In our precision medicine settings, the genomic features of patients may define the
eligibility to precision medicine and therefore affect A. They may also be used to define the version of treatment
K. And finally they can influence the response to treatment Y . Thus, the genomics features of patients, as defined
in section 1, are a typical example of type C confounders. All causal relationships are summarized in Figure 3.
Please note that all subsequent definitions are made taking into account W. However, no such variable is present in the
application provided.
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We summarize here some general observations from [8] regarding the extension of the framework to multiple versions
before discussing specific estimates of interest of our precision medicine settings in section 3.2.3. First of all, the
identifiability conditions have to be adapted. The consistency assumption for instance is extended to K:
if Aj = a, then Kaj (a) = K
a
j
.
Then, the conditional exchangeability or no-unmeasured confounding assumptions, may be stated in two different
ways, either without or with versions of treatment:
Y (a) ⊥⊥ A|(C,W ) (2)
Y (a, ka) ⊥⊥ {A,K}|C (3)
If equation 2 holds, we can derive a new version of the standardised estimator (Equation 1) with multiple versions of
treatment [8]:
E[Y (a)] = E[Y (a,Ka(a))] =
∑
c,w
E[Y |A = a,C = c,W = w]× P [c, w] (4)
Specifically, it should be noted that we need to add W in the set of covariates that must be taken into account in
standardization, and we need positivity to hold for C and W , i.e. 0 < P [A = a|C = c,W = w] < 1. Detailed proof
of equation 4 is provided in Supplementary Materials, section A. Equation 4 paves the way to overall treatment effect
assessment since E[Y (1,K1(1))]−E[Y (0,K0(0))] would estimate the effect of treatment A = 1 compared to A = 0
with current versions of treatment.
Conversely, estimating a treatment effect for a given unique version of treatment E[Y (a, ka)] would require to control
for exchangeability with versions K and therefore to hold equation 3 true [8]:
E[Y (a, ka)] =
∑
c
E[Y |A = a,Ka = ka, C = c]× P [c] (5)
Similarly, we can define Ga a random variable for versions of treatment with conditional distribution P [Ga = ka|C =
c] = gk
a,c and assuming the equation 3 to be true we can derive the following formula and its formal proof in
Supplementary Materials, section A:
E[Y (a,Ga)] =
∑
c,ka
E[Y |A = a,Ka = ka, C = c]× gka,c × P [c] (6)
In this case, to allow estimation of the right-hand side of the equation, positivity will be defined as 0 < P [A =
a,Ka = ka|C] < 1.
3.2.3 Application to precision medicine
In the context of the potential outcomes framework extended to treatments with multiple versions, it is therefore
possible to apply equations 4 and 6 in order to define and estimate the precision medicine causal effects previously
described in section 2.
A = 0 corresponds to control patients with K0 = {k0} and A = 1 to patients treated with a targeted treatments. It
is important to notice that from this point on we systematically restrict ourselves to patients eligible to the precision
medicine algorithm, i.e. to individuals j such as Cj ∈ CPM .
CE1 estimation
CE1 is a comparison between the precision medicine arm and a single version control arm:
CE1 = E[Y (1, r(C)]− E[Y (0, k0)] (7)
6
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In details, E[Y (1, r(C)] can be derived from equation 6 in the case where gk
a, c = 1 if ka = r(c) and gk
a, c = 0
otherwise:
E[Y (1, r(C)] =
∑
c
E[Y |A = 1,K1 = r(c), C = c]× P [c]
Then, E[Y (0, k0)] and E[Y (1, k1ref )] can be derived from equation 5:
E[Y (0, k0)] =
∑
c
E[Y |A = 0, C = c]× P [c]
Alternatively, if one wants to use as control only one of the treatments used in the PM arm the previous estimate could
be replaced by the following one:
E[Y (1, k1ref )] =
∑
c
E[Y |A = 1,K1 = k1ref , C = c]× P [c]
It should be noted that CE1, like CE2 and CE3 presented later, depends on the PM algorithm of interest r. CEi could
therefore also be written CE1(r).
CE2 estimation
Then, CE2 is written using K1(1) the PM targeted treatment that would have been assigned to the patient by the
physician if the patient had been allocated in arm A = 1 with PM targeted treatments:
CE2 = E[Y (1, r(C)]− E[Y (1,K1(1))] (8)
E[Y (1,K1(1))] is derived from equation 4:
E[Y (1,K1(1))] =
∑
c,w
E[Y |A = 1, C = c,W = w]× P [c, w]
CE3 estimation
Defining G1 as the random distribution of versions of treatment k1 ∈ K1, CE3 expresses as:
CE3 = E[Y (1, r(C)]− E[Y (1, G1)] with P [G1 = k1i ∈ K1] =
1
|K1PM |
, (9)
|.| denoting the cardinality of the set. In this formula, E[Y (1, G1)] can be derived from equation 6:
E[Y (1, G1)] =
1
|K1PM |
×
∑
c,k1i
E[Y |A = 1,K1 = k1i , C = c]× P [c]
3.3 Alternative estimation methods
For the sake of simplicity and brevity, we detailed the standardization. However, other popular candidate methods can
be used. Estimators based on the inverse probability weighting (IPW) and targeted maximum likelihood estimation
(TMLE) will also be computed in the following sections. A description of the theoretical framework of these two
approaches and their adaptation to multiple versions of treatment is provided in Supplementary Materials, sections B
and C.
3.4 Code implementation
Computation of causal effects is implemented in R and the code is provided in the form of R notebooks (simulated data
and PDX data) as well as in the form of an RShiny application (simulated data only). All of these files are available in
the dedicated GitHub: https://github.com/JonasBeal/Causal_Precision_Medicine.
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Table 1: Intercepts and and linear coefficients in the linear models specified to simulate data.
Response variable Intercept Linear regression coeff.
Y ∼ C1 Y ∼ C2
Y (0, k0) 0 0 15
Y (1, k11) -25 -15 10
Y (1, k12) 0 0 -20
4 Simulation study
The proposed methods are first tested on simulated data in order to check the performance of the estimators in finite
sample sizes.
4.1 General settings
Using the R package lava, we simulate a super-population of 10000 patients with variables C, A, K and Y as in 3.
We first define two independent binary variables C1 and C2, representing mutational status of genomic covariates,
with a prevalence of 40%. By analogy with the PDX data presented in the next section, Y mimics the evolution of
tumour volume and a low value (a fortiori negative) corresponds to a better response. Y is therefore defined as a
continuous gaussian variable. For each counterfactual variable of response Y (a, ka), we specify the intercept and the
linear regression coefficients regarding influence of Ci as described in Table 1. Lower intercepts correspond to better
responses/more efficient drugs. Similarly, a negative regression coefficient between Y (a, kai ) and Cj means that the
gene Cj improves the response to kai . So all in all, k
1
1 has the best basal response (lowest intercept). C1 (resp. C2)
improves the response to k11 (resp. k
1
2). The treatment algorithm of precision medicine is in line with these settings
since patients mutated in C1 (regardless their C2 status) are recommended to take k11 and patients mutated for C2
only are recommended to take k12 . Patients without mutations are not eligible to precision medicine and not taken into
account in the computations. Since k11 has the bast basal response we assume it is assigned with greater probability by
the physician and implement the following distribution of observed treatments:
P [K = k11] = 0.5 and P [K = k
1
2] = P [K = k
0] = 0.25
A super-population of 10000 patients is then generated. 1000 cohorts of 200 patients are sampled without replacement
within this super-population which, with the prevalences defined for the mutations, corresponds to an effective sample
size of about 130 patients eligible to the PM algortithm. the causal effects CE1, CE2 and CE3 are computed based on
different methods on the sub-cohort eligible to precision medicine:
• True effects, using counterfactuals for all patients
• Naive effect, using observed outcomes only for both arms
• Corrected effects: using observed outcome, computed with standardized estimators (Std), inverse probability
weighting (IPW) and targeted maximum likelihood estimators (TMLE). Details about estimators of the last
methods are available in Supplementary Materials, sections B and C.
4.2 Simulation results
First, the distribution of data in the super-population of 10,000 patients can be observed in Figure 4A, illustrating the
different relations and differences described above. In particular, Y (1, k11) (resp. Y (1, k
1
2)) is lower for C1-mutated
(resp. C2-mutated) patients. It can also be seen that the response to precision medicine (Y (1, r(C))) differs according
to the groups: patients mutated for C1 only have the best response, followed by patients mutated for both C1 and C2
and patients mutated for C2 only. There is therefore a heterogeneity of responses to PM which encourages to take into
account the groups of patients and their PM versions. The right side of Figure 4A shows the deterministic assignment of
the recommended PM treatment (r(C)) to each patient profile and the unbalanced distribution of observed treatments
(K) with a predominance of k11 .
In the first target trial, true CE1 estimates in the sampled cohorts are distributed around -40 (Figure 4B), confirming the
superiority of the PM arm over the control arm as defined in the simulation parameters. Not all methods of estimating
the causal effect perform equally well. The so-called naive estimate and the one based on IPW show a net bias. The
over-representation of the most advantaged patients by PM tends to cause these methods to overestimate the benefit
8
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Figure 4: Causal effects of PM with simulated data. (A) Main variables and relations in the simulated super-
population. From left to right: categories of patient based on their mutations; responses to k0, k11 , k
1
2 and precision
medicine K = r(C); repartition of patients regarding their precision medicine drug and their assigned treatment in
observed data. (B) Distribution and deviation of CE1 estimates based on different methods, deviation scores being
computed based on mean absolute error (MAE). (C) Same for CE2. (D) Same for CE3.
of PM, as can also be seen in the deviation plots. The same trends are observed for CE2 and CE3 (Figure 4C and D)
where the differences are even more drastic. The mean absolute error of the naive method is thus divided by more than
2 when using standardized estimates or the TMLE.
In order to further dissect the influence of simulation parameters on estimation performances, a slightly different simu-
lation scenario with equal probabilities of observed treatments is provided in Supplementary Materials, section D. This
case shows that a random and balanced assignment of the observed treatments logically removes the systematic biases
of the naive method by providing them with more randomized data. However, the corrections made by the proposed
methods of causal inference, and in particular standardization and TMLE, reduce the variances in the estimates due to
the heterogeneity of the effects of precision medicine as a function of molecular profiles.
9
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5 Application to pre-clinical data: patient-derived xenografts (PDX)
The method is then applied to public data from patient-derived xenografts [18]. Each patient tumour is divided into
pieces later implanted in several immunodeficient cloned mice treated with different drugs, thus providing access to
sensitivities to several different drugs for each tumour (see Supplementary Materials, section E). The original dataset
contains 281 different tumours of origin (sometimes called PDX models, in the sense of a biological model) and 63
tested drugs, not all drugs having been tested for all tumours [19]. 192 of these tumours have also been characterized
for their mutations, copy-number alterations and mRNA.
Such data provides access to treatment response values otherwise considered as hypothetical (or counterfactual). Avail-
ability of these data provides a unique ground truth to assess the validity of proposed causal estimates in a pre-clinical
context. Based on the analysis accompanying the published data [19], some biomarkers of treatment response have
been selected and resulted in an example of a treatment algorithm: binimetinib (MEK inhibitor) is recommended to
KRAS/BRAF mutated tumours, and BYL719 (alpha-specific PI3K inhibitor, also known as Alpelisib) to PIK3CA
mutated tumours. PTEN is also included as a covariate because of its detrimental impact on the response to these two
treatments. LEE011 drug (a cell cycle inhibitor also known as Ribociclib) is chosen as the reference drug treatment
(k0). It should be noted that different drug response metrics are computed in the source data, two of which will be used
in this case study. The first one is continuous and called BestAverageResponse in the data, it is based on the variation of
the tumour volume after treatment, the lower values (and especially negative) corresponding to better responses. The
second one is originally categorical and based on a modified Response Evaluation Criteria In Solid Tumors (RECIST)
criteria. It was binarized for this study so that the responders have a score of 1 and non-responders 0. The details of the
definition and distribution of these metrics are given in Supplementary Materials, section E. Among the sequenced tu-
mours, 88 are eligible to this precision medicine algorithm (i.e. mutated for BRAF, KRAS or PIK3CA) and have been
tested for all 3 drugs of interest, thus ensuring a the availability of all responses of interest. The following analyses
will focus exclusively on this sub-cohort for which a comprehensive analysis is provided in Supplementary Materials,
section E.
The analysis settings are similar to the ones used for simulated data. 1000 different cohorts of 70 tumours (out of 88)
are sampled without replacement assuming each time that only the response to one of the treatments is known for each
tumour, reproducing the classical clinical situation. The distribution of the observed treatments was defined randomly:
P [K = k0] = P [K = k11] = P [K = k
1
2] =
1
3
It should be noted that, contrary to analyses based on simulated data, all the statistical models used for standardisation
(outcome model), for the IPW (treatment model) and for the TMLE are no longer generalized linear models (GLM)
but random forests. This is intended to avoid misspecification due to the largely non-linear nature of the data. It was
also observed that the performance of GLM-based methods was indeed lower than that of the naive method, supporting
the importance of relevant model specification consistent with real data.
The results of estimations are then presented in Figure 5. In the presence of randomly assigned and balanced observed
treatments, none of the methods (including the naive one) has significant systematic bias. On the other hand, more
sophisticated methods, and in particular TMLE, allow to reduce the gap between estimates and true values, which is
achieved through the special design of the PDX data.
6 Discussion
In synthesis, this work proposes a conceptual framework for evaluating a precision medicine algorithm, taking advan-
tage of data already generated using adapted causal inference tools. In a clinical context, these data were not generated
in a purely observational manner. Patients were cared for and treated by physicians who probably took into account
some of their characteristics. However, the reasoning, formalized or not, behind the physicians’ decisions does not
correspond to that which a new investigator might want to test. In the eyes of this new investigator, the data can there-
fore be considered as observational in that they do not correspond to the randomization he would have liked to have
carried out. The possibility for this new investigator to estimate the impact of his PM algorithm using the proposed
estimators depends, however, on the consistency, exchangeability and positivity hypotheses.
The hypothesis of consistency has been made more plausible by taking into account the treatment versions, which
makes it possible to explicit the heterogeneity of the molecules administered. Exchangeability remains questionable.
The simulations and calculations described above underline the importance of taking into account at least the genomic
covariates used in the processing algorithm. The inclusion of additional covariates is likely to be necessary in many
real-world applications. Positivity, on the other hand, can be violated in a much more obvious way in certain situations.
Thus, equation 6 requires positivity to be extended to versions of treatment: 0 < P [A = a,Ka = ka|C] < 1. If
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Figure 5: Causal estimates with PDX data. Distribution and deviation of CE1 (A), CE2 (B) and CE3 (C) estimates
based on different methods
the assignment of the observed treatments was done on a deterministic basis with respect to the variables used by the
treatment algorithm, each patient’s molecular profile will have been treated with a single drug, thus preventing any
subsequent causal inference within the defined framework. The eventual use, by the boards of physicians in charge of
assigning the observed treatments, of variables different from those used by the algorithm could then make it possible
to verify the positive condition. But these variables would represent unmeasured confounding factors. It is therefore
essential to have an in-depth knowledge of the rationales at work in the assignment of the observed treatments.
We developed a user-friendly application that extends the scope of the simulations and makes possible to study and
quantify the impact of different situations, including possible (quasi-) violations of positivity or unmeasured con-
founding. It is thus a tool for empirically framing cases where this causal inference is reasonable or not. The analysis
of the PDX data provides an illustration and proof of feasibility for these methods on pre-clinical data, closer to the
human clinical data generally of interest. Beyond feasibility, this implementation leads to some remarks. Firstly, the
improvement of causal inference methods compared to naive estimation of PM effects is conditioned in this case to
the use of flexible and non-linear learning algorithms. This underlines the importance of a proper specification of
the outcome and treatment models whose imperfection, especially when trained on small samples, could explain the
modesty of the results compared to the simulated data. The particular nature of the PDX data design used should also
be kept in mind: each tumour is tested only once for each drug, which may lead to greater variability of results due to
tumour heterogeneity [19]. Some studies, with smaller numbers of tumours and treatments, propose to form groups
of several mice for each treatment-drug combination [18]. The use of these mean effects could contribute to more
accurate data. In spite of these limitations, which may diminish their ability to provide values with counterfactual
interpretation, PDX data are thus a dataset of interest for studying and validating methods of causal inferences about
treatment response. It can also be noted that the very nature of these data, due to the multiplicity of drugs tested for
each tumour, can provide a framework in which the constraints of positivity are singularly alleviated. Even if all drugs
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were not tested on all patients, considering each tumour-drug combination as a different unit increases the coverage of
the data. It is then necessary to take into account the clustered nature of the data, each tumour being present several
times.
Finally, beyond the preclinical data presented here, the theoretical framework developed in this article should be more
directly applicable to data from clinical trials if these data do not violate the requirements of positivity. If it is necessary
to consider several trials, the heterogeneity of practices must be taken into account. The use of different drug lists from
one trial to another or from one medical centre to another could also provide an example of confounding factor W ,
included in the theoretical framework presented here but not used in applications.
7 Software
All analyses have been performed with R. Analysis on simulated data is available as R code organized in a note-
book and also as a RShiny interactive application designed to test different simulation scenarios. Analysis on PDX
data is available as R notebook and the original dataset is also provided. All files and documentation are avail-
able on the dedicated GitHub repository: https://github.com/JonasBeal/Causal_Precision_Medicine. For
the interactive application, readers unfamiliar with R can refer to the online version of the RShiny application:
https://jonasbeal.shinyapps.io/application_causal_pm/.
8 Supplementary Materials
Theoretical details are given about standardised estimators in section A, about IPW estimators in section B and about
TMLE in section C. Section D showcases an additional scenario with simulated data. An extensive analysis of PDX
data is also provided in section E. Section F is focused on an example with a binary Y outcome.
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A Formal proofs for standardized causal estimates
The main notations and definitions have been described in the body of the article. Details of some
equations are provided below.
A.1 Unique version of treatment
Here is the formal proof for equation 3.1:
E[Y (a)] =
∑
c
E[Y (a)|c]× P [c]
=
∑
c
E[Y (a)|a, c]× P [c, w] by conditional exchangeabilityY (a) ⊥⊥ A|C
=
∑
c
E[Y |a, c]× P [c] by consistency for Y
A.2 Overall treatment effect with multiple versions of treatment
Here is the formal proof for equation 3.4, mostly derived from the proof of Proposition 3 in [1].
E[Y (a,Ka(a))] = E[Y (a)] Kais the version actually received
=
∑
c,w
E[Y (a)|c, w]× P [c, w]
=
∑
c,w
E[Y (a)|a, c, w]× P [c, w] with Y (a) ⊥⊥ A|(C,W )
=
∑
c,w
E[Y (a,Ka(a))|a, c, w]× P [c, w]
=
∑
c,w,ka
E[Y (a, ka)|a,Ka(a) = ka, c, w]× P [Ka(a) = ka|a, c, w]× P [c, w]
=
∑
c,w,ka
E[Y (a, ka)|a,Ka = ka, c, w]× P [Ka = ka|a, c, w]× P [c, w] (consistency for K)
=
∑
c,w,ka
E[Y |a,Ka = ka, c, w]× P [Ka = ka|a, c, w]× P [c, w] by consistency for Y
=
∑
c,w
E[Y |a, c, w]× P [c, w]
1
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Then, the overall treatment effect can be defined and computed by:
E[Y (a,Ka(a))]− E[Y (a∗,Ka∗(a∗))]
A.3 Treatment effect with predefined distributions of versions of treat-
ment
Here is the formal proof for equation 3.6, partially derived from the proof of Proposition 5 in [1].
E[Y (a,Ga)] =
∑
c
E[Y (a,Ga)|C = c]× P [c]
=
∑
c,ka
E[Y (a, ka)|Ga = ka, C = c]× P [Ga = ka|C = c]× P [c]
=
∑
c,ka
E[Y (a, ka)|C = c]× gka,c × P [c] since P [Ga = ka] = gka,c
=
∑
c,ka
E[Y (a, ka)|A = a,Ka = ka, C = c]× gka,c × P [c] with Y (a, ka) ⊥⊥ {A,K}|C
=
∑
c,ka
E[Y |A = a,Ka = ka, C = c]× P [c] by consistency for Y
2
B Theoretical framework for estimates based on inverse prob-
ability weighting (IPW)
Based on the same counterfactual framework, it is possible to build another class of models, called
marginal structural models [2], from which we derive estimators different from the standardized
estimators called inverse-probability-of-treatment weighted (IPW) estimators [3].
B.1 Generic notations and estimators
IP weighting is equivalent to creating a pseudo-population where the link between covariates and
treatment is cancelled. In the case of binary treatment A ∈ 0, 1, weights are defined for each patient
as the inverse of the probability to have received the version of treatment he or she actually received,
knowing his or her covariates:
WA =
1
f [A|C] with f [a|c] = P [A = a|C = c],
f [a|c] being called the propensity score, i.e. the probability to have received the treatment
A = a, given the covariates C = c. Under the same hypothesis of exchangeability, positivity and
consistency we can derive the modified Horvitz-Thompson estimator [4]:
E[Y (a)] =
Eˆ[I(A = a)WAY ]
Eˆ[I(A = a)WA]
,
I being the indicator function. It is also possible to define stabilized weights that will be used
in this work:
SWA =
f(A)
f [A|C] .
B.2 Extension to multiple version
An extension of these IPW methods to multi-valued treatments (only treatment K with different
modalities and no A) has already been studied and the different formulas and estimators adapted
accordingly [5, 6], defining in particular a generalized propensity score:
f(k|c) = P [K = k|C = c] = E[I(k)|C = c]
with I(k) =
{
1 if K = k
0 otherwise
and a subsequent estimator:
E[Y (k)] =
Eˆ[I(K = k)WKY ]
Eˆ[I(K = k)WK ]
with WK =
1
f [K|C]
B.3 Application to precision medicine estimates
In our case, to be consistent with the previously defined causal diagram we have both A, binary
status depending on the class of drugs, and K, the multinomial variable for versions of treatments,
i.e. the precise drug. Therefore we need to define a slightly different propensity score with joint
probabilities:
f(a, k|c) = P [A = a,K = k|C = c] = P [K = k|A = a,C = c].P [A = a|C = c] = E[I(a, k)|C = c]
3
with I(a, k) =
{
1 if A = a,K = k
0 otherwise
From this we can deduce the estimator:
E[Y (a, k)] =
Eˆ[I(A = a,K = k)WA,KY ]
Eˆ[I(A = a,K = k)WA,K ]
with WA,K =
1
f [A,K|C]
In all the examples presented in this study and implemented in the code, K0 ∩ K1 = ∅, it is
therefore possible to simplify the joint probabilities since the knowledge of K automatically results
in the knowledge of A allowing P [A = a,K = k|C = c] = P [K = k|C = c]. The above formulas
with the attached probabilities are still necessary in the general case and allow for the derivation
of causal effects CE1, CE2 and CE3 previously described.
4
C Some elements about targeted maximum-likelihood esti-
mation (TMLE)
Targeted maximum likelihood estimation is framework based on a doubly robust maximum-likelihoodbased
approach that includes a ”targeting” step that optimizes the bias-variance trade-off for a defined
target parameter. In particular, this method is perfectly compatible with the use of machine learn-
ing algorithms for outcome or treatment models. A detailed description of the method and its
implementations can be found in [7].
The implementation proposed in this article is very similar to the one proposed in a recent
tutorial concerning the application to binary processing [8]. The specific characteristics of the
problem of precision medicine studied here lead to modify this approach. In particular, the outcome
and treatment models used in the first steps are modified in the same way as the one explained for
the standardized estimators (outcome model) and for the IPW estimators (treatment model). The
step of updating the estimates is done on a model similar to [8].
The algorithm used for the models internal to the TMLE are, as much as possible, the same as
those used for the standardised and IPW estimators. For simulated data generalized linear models
have been used in all cases except multinomial classification andperformed through the function
multinom in nnet package. For PDX data, random forests have been used for all models; use of
SuperLearner is made possible by simple modifications to the code but significantly slows down its
execution. In the latter case random forests were chosen for their speed and versatility, especially
in view of their ability to handle multinomial classification as well.
5
D An additional simulation scenario
For this first scenario, observed treatments are assigned randomly with equal probabilities:
P [K = k0] = P [K = k11] = P [K = k
1
2] =
1
3
Although this scenario is not necessarily the most clinically plausible, it allows us to observe the
impact of treatment and response heterogeneity on effect estimates. The main features of generated
data is described in Figure S1A. The results of estimation of causal effects using different methods
are summarized in Figure S1B, C and D. First of all, we observe that the PM arm is estimated
to be better than the 3 controls, which is logical with the way the data were simulated, with a
treatment algorithm perfectly adapted to the data generation process. Besides, random assignment
of the observed treatments prevents the naive method from being systematically biased, but it does
not prevent it from demonstrating greater variance and mean absolute error.
6
Figure S1: Causal effects of PM with simulated data. (A) Main variables and relations in
the simulated super-population. From left to right: categories of patient based on their mutations;
responses to k0, k11, k
1
2 and precision medicine K = r(C); repartition of patients regarding their
precision medicine drug and their assigned treatment in observed data. (B) Distribution and devia-
tion of CE1 estimates based on different methods, deviation scores being computed based on mean
absolute error (MAE). (C) Same for CE2. (D) Same for CE3.
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E Additional information about patient-derived xenografts
(PDX) data
Patient-derived xenografts have been used in different settings which nevertheless take up the same
fundamentals: implanting a tumour from a patient in an immunodeficient mouse in order to observe
its evolution and ideally its response to treatment. This therefore provides an intermediate pre-
clinical model between the patient and the in vitro cell lines that do not take into account the
tumour micro-environment. A more precise description of these models and the different ways of
using them can be found in dedicated reviews [9] and the schematic representation that applies to
the data presented here is described in Figure S2.
Figure S2: Principles of PDX screening. Schematic pipeline for PDX screening with tumour
biopsies from one patient divides in several pieces later implanted in similar immunodeficient mice.
Each mouse is then treated with a different drug. The collection of mice that have received tumour
samples from the same patient but have been treated with different drugs therefore gives access to
outcomes otherwise considered as Counterfactual. This pipeline follows the ”one animal per model
per treatment” approach (1× 1× 1) as described in [10].
E.1 PDX data and drug response metrics
E.1.1 A continuous outcome
The first drug response metric used in this article is called Best Average Response. For each
combination tumour/drug, the response is determined by comparing tumor volume change at time
t, Vt to tumor volume at time t0, Vt0 . Several scores are computed:
Tumour Volume Change (%) = ∆V olt = 100%× Vt − Vt0
Vt
Best Response = min(∆V olt), t > 10d
Average Responset = mean(∆V oli, 0 ≤ i ≤ t)
Best Average Response = min(Average Responset), t > 10d
We will mainly focus on Best Average Response. This metric ”captures a combination of speed,
strength and durability of response into a single value” [10]. Qualitatively, lower values correspond
to more efficient drugs.
8
E.1.2 A binary outcome
Thresholds of Best Response and Best Average Response are also defined, inspired by RECIST
criteria [11], in order to classify response to treatment into 4 categories: Complete Response (CR),
Partial Response (PR, Stable Disease (SD) and Progressive Disease (PD). We designed a binary
response status by combining the response categories (CR, PR and SD) into a single ’responder’
category (1), opposed to the ’non-responders’ progressive diseases (0).
E.2 General description of the 88 PDX models sub-cohort
Treatment assignment algorithm and observed drug sensitivities are consistent since mutated BRAF/KRAS
tumours have a better response to binimetinib and mutated PIK3CA tumours have a better re-
sponse to BYL719. In addition, it can be noted that these biomarkers have deleterious cross-effects.
Figure S3: Description of the 88 PDX models cohort. Tissue of origin and prevalences of the
drug biomarkers.
Figure S4: Drug response to PM treatments in the 88 PDX models cohort. Continuous
(A) and binary (B) response to binimetinib and BYL719 depending on the mutational status of
biomarkers.
9
F Causal estimates with a binary outcome
An analysis similar to the one presented in section 6 of the paper is detailed here, replacing the
continuous outcome with a binary response outcome. The definition of this binary outcome is given
in the previous section.
Figure S5: Causal estimates with PDX data binary outcome. Distribution and deviation of
CE1 (A), CE2 (B) and CE3 (C) estimates based on different methods
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